195 related articles for article (PubMed ID: 26390407)
1. Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine.
de Oliveira LM; Morale MG; Chaves AA; Cavalher AM; Lopes AS; Diniz Mde O; Schanoski AS; de Melo RL; Ferreira LC; de Oliveira ML; Demasi M; Ho PL
PLoS One; 2015; 10(9):e0138686. PubMed ID: 26390407
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
Zhu L; Cui X; Yan Z; Tao Y; Shi L; Zhang X; Yao Y; Shi L
Hum Vaccin Immunother; 2024 Dec; 20(1):2352908. PubMed ID: 38780076
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene.
Gao J; Fan L; Ma W; Xiao H
Microbiol Immunol; 2016 Sep; 60(9):626-33. PubMed ID: 27515281
[TBL] [Abstract][Full Text] [Related]
5. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
6. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
[TBL] [Abstract][Full Text] [Related]
7. Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling).
Almajhdi FN; Senger T; Amer HM; Gissmann L; Öhlschläger P
PLoS One; 2014; 9(11):e113461. PubMed ID: 25422946
[TBL] [Abstract][Full Text] [Related]
8. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
9. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
10. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
12. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
13. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
[TBL] [Abstract][Full Text] [Related]
14. [Transformation activity and antigenicity of the human papillomavirus type 58 E6E7 fusion gene mutant].
Wang H; Yu JY; Li L
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):491-6. PubMed ID: 24257298
[TBL] [Abstract][Full Text] [Related]
15. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
16. HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach.
Yao Y; Huang W; Yang X; Sun W; Liu X; Cun W; Ma Y
Vaccine; 2013 Apr; 31(18):2289-94. PubMed ID: 23499609
[TBL] [Abstract][Full Text] [Related]
17. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X
Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969
[TBL] [Abstract][Full Text] [Related]
18. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.
Oosterhuis K; Aleyd E; Vrijland K; Schumacher TN; Haanen JB
Hum Gene Ther; 2012 Dec; 23(12):1301-12. PubMed ID: 22971245
[TBL] [Abstract][Full Text] [Related]
19. Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches.
Sanami S; Azadegan-Dehkordi F; Rafieian-Kopaei M; Salehi M; Ghasemi-Dehnoo M; Mahooti M; Alizadeh M; Bagheri N
Sci Rep; 2021 Jun; 11(1):12397. PubMed ID: 34117331
[TBL] [Abstract][Full Text] [Related]
20. Customized Viral Immunotherapy for HPV-Associated Cancer.
Atherton MJ; Stephenson KB; Pol J; Wang F; Lefebvre C; Stojdl DF; Nikota JK; Dvorkin-Gheva A; Nguyen A; Chen L; Johnson-Obaseki S; Villeneuve PJ; Diallo JS; Dimitroulakos J; Wan Y; Lichty BD
Cancer Immunol Res; 2017 Oct; 5(10):847-859. PubMed ID: 28912369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
